Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics develops clinical-stage cardiopulmonary therapies, with news centered on levosimendan and TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company describes itself as a Phase 3, development-stage pharmaceutical company and reports on the LEVEL and LEVEL-2 registrational programs, intellectual property, and global development rights for levosimendan.
Recurring announcements also cover financial results, corporate updates, investor conference participation, executive appointments, and equity-based inducement grants under Nasdaq rules. These updates connect Tenax's drug-development program with governance, finance, product-development, clinical operations, and commercial-preparation activities.
Tenax Therapeutics (Nasdaq: TENX) announced that President & CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. A live and archived webcast will be available via the company’s investor relations webpage.
Tenax Therapeutics (Nasdaq: TENX) reported full Phase 3 LEVEL trial analyses of TNX-103 (oral levosimendan) in pulmonary hypertension due to HFpEF at ESC Congress 2026. In the overall 241‑patient population, the primary endpoint (12‑week change in 6‑minute walk distance) and key secondary KCCQ-TSS endpoint did not reach statistical significance.
Prespecified and post-hoc analyses identified a concentration of treatment effect in patients with baseline 6MWD below the trial median of 333 meters (n = 119). In this subgroup, TNX‑103 showed a placebo‑adjusted 6MWD improvement of 26.3 meters (p = 0.0112), a 47% NT-proBNP reduction (p < 0.0001), and a 4.9 mmHg RVSP reduction (p = 0.009). According to Tenax, TNX‑103 was safe and well tolerated, and the results will guide protocol enrichment and the planned LEVEL‑2 registrational path focused on patients with lower baseline walk distance.
Tenax Therapeutics (Nasdaq:TENX) reported topline Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in patients with PH-HFpEF. The study (n=241) did not meet its primary endpoint of change in 6‑minute walk distance (least-squares mean difference 3.5 meters; p=0.63) or the key secondary endpoint KCCQ total symptom score.
Prespecified subgroup and exploratory analyses showed signals of activity: patients with baseline walk distance <333 meters had a 26.3‑meter improvement versus placebo (95% CI 6.0, 46.7; nominal p=0.0112). In the overall population, TNX‑103 produced a 49% greater reduction in NT‑proBNP versus placebo (nominal p<0.0001) and a 3.5 mmHg reduction in RVSP (nominal p=0.0045). Serious adverse events were similar between arms (10.8% vs 10.7%), and TNX‑103 was generally well tolerated, though overall adverse events were more frequent on treatment (86.7% vs 71.9%).
According to Tenax, it plans to request a Type C FDA meeting, seek EMA scientific advice, pursue an enrichment strategy focused on higher-burden patients, and present full LEVEL data at ESC Congress 2026.
Tenax Therapeutics (Nasdaq:TENX) reported second quarter 2026 results and a corporate update for its Phase 3 cardiopulmonary programs. As of June 30, 2026, cash and cash equivalents were $118.0 million, supported by $13.4 million in warrant exercise proceeds, which the company expects will fund operations through the second quarter of 2028.
Q2 2026 research and development expenses were $12.9 million versus $6.1 million a year earlier, mainly from the Phase 3 LEVEL and LEVEL-2 trials of oral levosimendan (TNX-103). Selling, general and administrative expenses were $5.9 million versus $5.7 million, and net loss was $17.8 million versus $10.9 million. Tenax expects topline LEVEL data in August 2026 and plans a late-breaking presentation at ESC 2026, while LEVEL-2 enrollment is ongoing with completion targeted by year-end 2027.
Tenax Therapeutics (Nasdaq:TENX) granted non-qualified stock options as Nasdaq Listing Rule 5635(c)(4) inducement awards to three newly hired, non-executive employees in accounting, clinical operations, and CMC/product development roles.
The July 1, 2026 grants cover an aggregate 160,000 shares, with time-based vesting over four years.
Tenax Therapeutics (Nasdaq:TENX) will present Phase 3 LEVEL trial data as a Late-Breaking Clinical Science session at ESC Congress 2026 in Munich. The registrational study evaluates TNX-103 (oral levosimendan) in PH-HFpEF. Topline results are expected in August 2026 following database lock and analysis.
Tenax Therapeutics (Nasdaq:TENX) reported first quarter 2026 results and a corporate update. Cash and equivalents were $118.8 million, expected to fund operations through at least Q1 2028. The Phase 3 LEVEL trial of TNX-103 has randomized all patients, with topline data expected in Q3 2026, while global Phase 3 LEVEL-2 enrollment is ongoing and anticipated to complete by end of 2027. Leadership additions include a new CFO, CCO and an EVP of Clinical Development and Strategy. Q1 2026 R&D expenses were $11.5 million, G&A was $5.0 million, and net loss was $15.7 million.
Tenax Therapeutics (Nasdaq: TENX) awarded inducement option grants to four newly hired non-executive employees between April 28, 2026 and June 1, 2026. The aggregate award equals 657,500 non-qualified stock options with exercise prices set at each hire date's Nasdaq close.
Vesting: 25% on the first anniversary, then 36 substantially equal monthly installments thereafter, subject to continued service. Grants were approved by the Board's Compensation Committee and issued outside the company's stockholder-approved equity incentive plan per Nasdaq Listing Rule 5635(c)(4).
Tenax Therapeutics (NASDAQ: TENX) appointed Timothy Healey, MBA as Chief Commercial Officer, effective immediately on May 4, 2026. Healey joins from Eversana and previously held senior commercial roles at Lantheus, AbbVie, and AMAG.
He will lead global commercial strategy and prepare TNX-103 and the company for a potential commercial launch, developing processes and capabilities to support commercialization.
Tenax Therapeutics (NASDAQ: TENX) appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026. Mr. Staab has over 25 years of healthcare finance leadership and succeeds interim CFO Thomas McGauley. Tenax granted inducement awards: 10,000 RSUs and options to purchase 450,000 shares, vesting over one year and monthly thereafter.
The option exercise price will equal the closing common stock price on the grant date; awards were approved under Nasdaq Rule 5635(c)(4).